We are a clinical-stage biopharmaceutical company leveraging our proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Our platform enables us to strategically pair linker-payloads that modulate key disease-modifying pathways with monoclonal antibodies directed to specific disease sites. Initially, we are creating a new class of targeted immuno-oncology agents that direct a myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing.
Location: United States, Washington, Seattle
Employees: 51-200
Total raised: $211M
Founded date: 2016
Investors 6
| Date | Name | Website |
| - | US Venture... | usvp.com |
| - | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
| - | Timefolio ... | timefolioc... |
| - | EcoR1 Capi... | ecor1cap.c... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 23.09.2020 | Series C | $85M | - |
| 11.03.2020 | Series B | $78.5M | - |
| 23.09.2018 | Series A | $47.5M | - |
Mentions in press and media 15
| Date | Title | Description |
| 30.11.2020 | Seattle biotech firm Silverback Therapeutics sets terms for IPO, looks to raise up to $151M | Laura Shawver, CEO of Silverback Therapeutics. (Silverback Photo) Silverback Therapeutics plans to raise up to $151.8 million in its initial public offering, the Seattle-based company said Monday in an updated IPO filing. The biotech firm w... |
| 23.09.2020 | Silverback Therapeutics Raises $85M in Series C | SEATTLE, WA, Silverback Therapeutics announced the close of an $85 million Series C financing round led by EcoR1 Capital. >> Click here for more funding data on Silverback Therapeutics >> To export Silverback Therapeutics fu... |
| 23.09.2020 | Silverback Therapeutics Raises $85 Million in Series C Financing; Company Announces Executive Promotions | - |
| 23.09.2020 | Silverback Therapeutics Raises $85 Million in Series C Financing; Company Announces Executive Promotions | - |
| 23.09.2020 | Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | After banking $78.5 million six months ago, Silverback Therapeutics is back for more. The immuno-oncology biotech is picking up another $85 million to advance its lead antibody-drug conjugate (ADC) through the clinic and to develop its earl... |
| 23.09.2020 | Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | After banking $78.5 million six months ago, Silverback Therapeutics is back for more. The immuno-oncology biotech is picking up another $85 million to advance its lead antibody-drug conjugate (ADC) through the clinic and to develop its earl... |
| 23.09.2020 | Silverback Therapeutics Raises $85M in Series C Financing | Silverback Therapeutics, Inc., a Seattle, WA-based clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue-targeted therapeutics for the treatment of can... |
| 11.03.2020 | Silverback Therapeutics Inks $78.5M in Series B | SEATTLE, WA, Silverback Therapeutics announced the close of an oversubscribed $78.5 million Series B financing round led by U.S. Venture Partners. >> Click here for more funding data on Silverback Therapeutics >> To export S... |
| 11.03.2020 | Silverback Therapeutics Raises $78.5 Million in Oversubscribed Series B Financing | - |
| 11.03.2020 | Silverback Therapeutics Raises $78.5 Million in Oversubscribed Series B Financing | - |
Show more